Therefore, in the present study we for the first time performed a case-control study to explore systematically the correlation of PI3K/PTEN/AKT pathway genetic variations with the susceptibility, clinicopathological features, and response to treatment and clinical outcomes of BC patients after CE(A)F regimen. This evidence concerns the gene AKT1 and breast cancer.